Labcorp Holdings Inc. (LH)
| Market Cap | 17.09B |
| Revenue (ttm) | 12.30B |
| Net Income (ttm) | 433.10M |
| Shares Out | 84.29M |
| EPS (ttm) | 5.06 |
| PE Ratio | 40.07 |
| Forward PE | 13.07 |
| Dividend | $2.88 (1.42%) |
| Ex-Dividend Date | May 28, 2024 |
| Volume | 394,843 |
| Open | 203.13 |
| Previous Close | 203.13 |
| Day's Range | 201.86 - 203.92 |
| 52-Week Range | 191.97 - 234.09 |
| Beta | 1.03 |
| Analysts | Buy |
| Price Target | 242.08 (+19.41%) |
| Earnings Date | Jul 25, 2024 |
About LH
Labcorp Holdings Inc. operates as a laboratory services company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C te... [Read more]
Financial Performance
In 2023, LH's revenue was $12.16 billion, an increase of 2.51% compared to the previous year's $11.86 billion. Earnings were $418.00 million, a decrease of -67.32%.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for LH stock is "Buy." The 12-month stock price forecast is $242.08, which is an increase of 19.41% from the latest price.
News
Labcorp to Announce Second Quarter Financial Results on August 1, 2024
BURLINGTON, N.C. , July 1, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 20...
Labcorp Launches Global Trial Connect to Accelerate Clinical Trials
Suite of digital and data solutions designed to improve clinical trial efficiency, reduce data delays and simplify investigator site workflows BURLINGTON, N.C. , June 17, 2024 /PRNewswire/ -- Labcorp ...
Labcorp Announces New Strategic Service Offerings within Precision Oncology Portfolio
Labcorp® Tissue Complete, a comprehensive genomic profiling service, now available in Geneva and Shanghai to support global clinical trials Company expands leadership in liquid biopsy comprehensive ge...
Labcorp to Present Multiple Abstracts across Precision Oncology at the 2024 ASCO Annual Meeting
Abstracts offer insights into precision oncology diagnostics for triple-negative breast cancer, liquid biopsy and machine learning for tumor profiling BURLINGTON, N.C. , May 30, 2024 /PRNewswire/ -- L...
Labcorp to Speak at the 44th Annual William Blair Growth Stock Conference
BURLINGTON, N.C., May 28, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team wi...
Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk during Pregnancy
Labcorp is now the only lab that can detect preeclampsia risk across all pregnancy trimesters BURLINGTON, N.C. , May 15, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comp...
Labcorp to Webcast Its Annual Meeting of Shareholders
BURLINGTON, N.C. , May 8, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that its Annual Meeting of Shareholders will be ...
Invitae Receives Court Approval for Sale to Labcorp
Acquisition advances Labcorp's specialty testing strategy in key areas such as oncology and rare diseases Key milestone reached in Invitae's Chapter 11 process BURLINGTON, N.C. and SAN FRANCISCO , May...
FDA Approves ColoSense™ – Geneoscopy's Noninvasive Multi-target Stool RNA (mt-sRNA) Colorectal Cancer Screening Test
ST. LOUIS--(BUSINESS WIRE)--Geneoscopy, Inc. announced that the U.S. Food and Drug Administration (FDA) approved its noninvasive colorectal cancer screening test, ColoSense.
FDA brings lab tests under federal oversight in bid to improve accuracy and safety
WASHINGTON — Makers of medical tests that have long escaped government oversight will have about four years to show that their new offerings deliver accurate results, under a government rule vigorousl...
Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B
Assay expands company's leadership in precision medicine and cell and gene therapy BURLINGTON, N.C. , April 29, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive...
Labcorp beats quarterly estimates on strong testing demand
Labcorp beat Wall Street expectations for first-quarter profit on Thursday, as growing demand for specialty tests boosted sales at its diagnostics business.
Labcorp Announces 2024 First Quarter Results
Updates Full-Year Guidance Results from Continuing Operations for first quarter 2024 versus last year: Revenue: $3.18 billion versus $3.04 billion or up 4.6% | Base Business grew 6.7% Diluted EPS: $2....
Clinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 mln
Laboratory service provider Labcorp said on Wednesday it will acquire Softbank-backed Invitae Corp's assets auctioned through a voluntary bankruptcy protection process, a few months after the genetic ...
Labcorp Announces Winning Bid for Select Assets of Invitae
Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 BURLINGTON, N...
Invitae Enters into Agreement with Labcorp for Sale of Business
– Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantially All of the Company's As...
Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw
Innovative GFAP blood biomarker test expands Labcorp's portfolio of tests for diseases including Alzheimer's disease, multiple sclerosis, glioblastoma and brain injuries BURLINGTON, N.C. , April 15, 2...
Labcorp Declares Quarterly Dividend
BURLINGTON, N.C. , April 11, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a ca...
Labcorp Receives FDA Emergency Use Authorization for Mpox PCR Test Home Collection Kit
The first at-home mpox testing kit provides patients with convenience and privacy to test for mpox, supports physicians in detection and treatment BURLINGTON, N.C. , April 10, 2024 /PRNewswire/ -- Lab...
Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs
Portfolio expansion solidifies company's commitment to advancing cancer research and patient care BURLINGTON, N.C. , April 8, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and...
Labcorp Launches Labcorp® Plasma Detect™ Extending Leadership into Molecular Residual Disease (MRD) Clinical Research
Labcorp Plasma Detect is the first clinically validated, whole-genome sequencing MRD solution for early-stage colon cancer BURLINGTON, N.C. , April 5, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global...
Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research
Researchers to present on topics ranging from molecular residual disease and immunotherapy to whole-genome sequencing BURLINGTON, N.C. , April 2, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global lead...
Xcell Biosciences Strengthens Cell and Gene Therapy Collaboration With Labcorp
SAN FRANCISCO--(BUSINESS WIRE)--Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene therapy applications, today announced it has added new elements to its research c...
The Prelude Network® Names Labcorp Its Preferred Genetic Carrier Screening Lab
Expanded partnership to help increase patient access to critical genetic screening services including genetic counseling and test result turnaround time HOUSTON , March 29, 2024 /PRNewswire/ -- The P...
Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business
Transaction to enhance Labcorp's laboratory services network and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI , March 28, 2024 /PRNewswire/ -- L...